Administration Methods of Mesenchymal Stem Cells in the Treatment of Burn Wounds
European Burn Journal · 03.11.2022 · 3 (4) · 493-516
DOI: 10.3390/ebj3040043 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Burn Journal, online erschienen am 03.11.2022. Verfasst von Astrid Bjørke Jenssen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Norwegian National Burn Center, Department of Plastic, Hand, and Reconstructive Surgery, Haukeland University Hospital, 5021 Bergen, Norway. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Trond Mohn Foundation.
Abstract (Originalsprache)
Cellular therapies for burn wound healing, including the administration of mesenchymal stem or stromal cells (MSCs), have shown promising results. This review aims to provide an overview of the current administration methods in preclinical and clinical studies of bone-marrow-, adipose-tissue-, and umbilical-cord-derived MSCs for treating burn wounds. Relevant studies were identified through a literature search in PubMed and Embase and subjected to inclusion and exclusion criteria for eligibility. Additional relevant studies were identified through a manual search of reference lists. A total of sixty-nine studies were included in this review. Of the included studies, only five had clinical data from patients, one was a prospective case–control, three were case reports, and one was a case series. Administration methods used were local injection (41% in preclinical and 40% in clinical studies), cell-seeded scaffolds (35% and 20%), topical application (17% and 60%), and systemic injection (1% and 0%). There was great heterogeneity between the studies regarding experimental models, administration methods, and cell dosages. Local injection was the most common administration method in animal studies, while topical application was used in most clinical reports. The best delivery method of MSCs in burn wounds is yet to be identified. Although the potential of MSC treatment for burn wounds is promising, future research should focus on examining the effect and scalability of such therapy in clinical trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Norwegian National Burn Center, Department of Plastic, Hand, and Reconstructive Surgery, Haukeland University Hospital, 5021 Bergen, Norway.
- Center for Translational Oral Research (TOR), Tissue Engineering Group, Department of Clinical Dentistry, Faculty of Medicine, University of Bergen, 5020 Bergen, Norway.
- Department of Pharmacology, Faculty of Medicine, University of Helsinki, 00014 Helsinki, Finland.
- Department of Clinical Medicine, Faculty of Medicine, University of Bergen, 5020 Bergen, Norway.
- Department of Anesthesia and Intensive Care, Haukeland University Hospital, 5021 Bergen, Norway.
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, 5020 Bergen, Norway.
ORCID-Profile: Astrid Bjørke Jenssen, Esko Kankuri, Kamal Mustafa, Stian Kreken Almeland
Förderung
- Trond Mohn Foundation
Zitieren
APA
Jenssen, A. B., Mohamed-Ahmed, S., Kankuri, E., Brekke, R. L., Guttormsen, A. B., Gjertsen, B. T., Mustafa, K., & Almeland, S. K. (2022). Administration Methods of Mesenchymal Stem Cells in the Treatment of Burn Wounds. European Burn Journal, 3(4), 493-516. https://doi.org/10.3390/ebj3040043
Vancouver
Jenssen AB, Mohamed-Ahmed S, Kankuri E, Brekke RL, Guttormsen AB, Gjertsen BT, et al. Administration Methods of Mesenchymal Stem Cells in the Treatment of Burn Wounds. European Burn Journal. 2022;3(4):493-516. doi:10.3390/ebj3040043
BibTeX
@article{Jenssen2022,
author = {Jenssen, Astrid Bjørke and Mohamed-Ahmed, Samih and Kankuri, Esko and Brekke, Ragnvald Ljones and Guttormsen, Anne Berit and Gjertsen, Bjørn Tore and Mustafa, Kamal and Almeland, Stian Kreken},
title = {Administration Methods of Mesenchymal Stem Cells in the Treatment of Burn Wounds},
journal = {European Burn Journal},
year = {2022},
volume = {3},
number = {4},
pages = {493--516},
doi = {10.3390/ebj3040043}
}
EUVIMED